U.S. FDA flags data integrity, contamination lapses at Dabur's Dadra plant

After a January inspection, the U.S. drug regulator cited Dabur India for falsified records, microbial contamination risks, poor maintenance and even a live bird in the raw material warehouse at its Dadra and Nagar Haveli facility, raising compliance concerns for the 140-year-old FMCG major.

— Source publishedFri, 29 May, 2026, 12:45 IST·First seen Fri, 29 May, 2026, 13:09 IST·Source ET Retail

What happened

U.S. FDA flagged data integrity, contamination and maintenance lapses at Dabur India's Dadra and Nagar Haveli plant after a January inspection, citing falsified

Key facts

  • Rs 400 crore
  • 140 years
  • 25%
  • 30 feet

Why this matters

Dabur's Dadra compliance lapses could open negotiating leverage on co-manufacturing or licensing deals while signaling broader due-diligence scrutiny needed across Indian personal-care supply chains.